{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:24:29Z","timestamp":1788780269670,"version":"build-2803163510"},"reference-count":30,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T00:00:00Z","timestamp":1599436800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005940","name":"Dansk Kr\u00e6ftforsknings Fond","doi-asserted-by":"publisher","award":["501100005940"],"award-info":[{"award-number":["501100005940"]}],"id":[{"id":"10.13039\/501100005940","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2020-0137_abs_001_w2aab3b7c21b1b6b1aab1c14b1Aa\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Carboplatin is frequently used in various doses for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of epithelial ovarian cancer (EOC) although its pharmacokinetics, including focus on the perfusion time, has not been evaluated when used in modern era cytoreductive surgery (CRS). The aim was to evaluate the pharmacokinetics and hematological toxicity of carboplatin used for HIPEC with a perfusion time of 90\u00a0min.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2020-0137_abs_002_w2aab3b7c21b1b6b1aab1c14b2Aa\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Fifteen patients with stage III\u2013IV primary EOC received CRS and 90\u00a0min of HIPEC with carboplatin at dose 800\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . For the pharmacokinetic analysis, perfusate and blood samples were obtained during HIPEC and up to 48\u00a0h after HIPEC (blood only). Hematological toxicity within 30\u00a0days was graded according to Common Terminology Criteria for Adverse Events. Severe toxicity (grades 3\u20135) is reported.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2020-0137_abs_003_w2aab3b7c21b1b6b1aab1c14b3Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Mean maximum concentration of carboplatin was 12 times higher in perfusate than plasma (mean CmaxPF=348\u00a0\u00b5g\/mL (range: 279\u2013595\u00a0\u00b5g\/mL) versus mean CmaxPL=29\u00a0\u00b5g\/mL (range: 21\u201339\u00a0\u00b5g\/mL)). Mean terminal half-life of carboplatin in perfusate was 104\u00a0min (range: 63\u2013190\u00a0min) and mean intraperitoneal-to-plasma area under the concentration-time curve (AUC) ratio was 12.3 (range: 7.4\u201317.2). Two patients (13%) had grade 3 neutropenia within 30\u00a0days. No grade 4\u20135 hematological toxicities were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2020-0137_abs_004_w2aab3b7c21b1b6b1aab1c14b4Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Carboplatin has a favorable pharmacokinetic profile for 90\u00a0min HIPEC administration, and the hematological toxicity was acceptable at dose 800\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . Large interindividual differences were found in the pharmacokinetic parameters, making risk of systemic exposure difficult to predict.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2020-0137","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T09:43:34Z","timestamp":1599471814000},"source":"Crossref","is-referenced-by-count":13,"title":["Pharmacokinetics and toxicity of carboplatin used for hyperthermic intraperitoneal chemotherapy (HIPEC) in treatment of epithelial ovarian cancer"],"prefix":"10.1515","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5943-7037","authenticated-orcid":false,"given":"Mette Schou","family":"Mikkelsen","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics , Aarhus University Hospital , Aarhus , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Blaakaer","sequence":"additional","affiliation":[{"name":"Department of Clinical Research , University of Southern Denmark , Odense , Denmark"},{"name":"Department of Gynecology and Obstetrics , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone Kjeld","family":"Petersen","sequence":"additional","affiliation":[{"name":"Open Patient Explorative Data Network, Department of Clinical Research , University of Southern Denmark , Odense , Denmark"},{"name":"Department of Gynecology and Obstetrics , Odense University Hospital , Odense , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise Gram","family":"Schleiss","sequence":"additional","affiliation":[{"name":"Discovery and Development PKPD , Novo Nordisk A\/S , Maaloev , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lene Hjerrild","family":"Iversen","sequence":"additional","affiliation":[{"name":"Department of Surgery , Aarhus University Hospital , Aarhus , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"2025120909220889696_j_pp-2020-0137_ref_001_w2aab3b7c21b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Webb, PM, Jordan, SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2017;41:3\u201314. https:\/\/doi.org\/10.1016\/j.bpobgyn.2016.08.006.","DOI":"10.1016\/j.bpobgyn.2016.08.006"},{"key":"2025120909220889696_j_pp-2020-0137_ref_002_w2aab3b7c21b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Orr, B, Edwards, RP. Diagnosis and treatment of ovarian cancer. Hematol Oncol Clin N Am 2018;32:943\u201364. https:\/\/doi.org\/10.1016\/j.hoc.2018.07.010.","DOI":"10.1016\/j.hoc.2018.07.010"},{"key":"2025120909220889696_j_pp-2020-0137_ref_003_w2aab3b7c21b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Morano, WF, Khalili, M, Chi, DS, Bowne, WB, Esquivel, J. Clinical studies in CRS and HIPEC: trials, tribulations, and future directions-a systematic review. J Surg Oncol 2018;117:245\u201359. https:\/\/doi.org\/10.1002\/jso.24813.","DOI":"10.1002\/jso.24813"},{"key":"2025120909220889696_j_pp-2020-0137_ref_004_w2aab3b7c21b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Vergote, I, Harter, P, Chiva, L. Is there a role for intraperitoneal chemotherapy, including HIPEC, in the management of ovarian cancer?. J Clin Oncol 2019;37:2420\u20133. https:\/\/doi.org\/10.1200\/jco.19.00091.","DOI":"10.1200\/JCO.19.00091"},{"key":"2025120909220889696_j_pp-2020-0137_ref_005_w2aab3b7c21b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Zivanovic, O, Chi, DS, Filippova, O, Randall, LM, Bristow, RE, O\u2019Cearbhaill, RE. It\u2019s time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer. Gynecol Oncol 2018;151:555\u201361. https:\/\/doi.org\/10.1016\/j.ygyno.2018.09.007.","DOI":"10.1016\/j.ygyno.2018.09.007"},{"key":"2025120909220889696_j_pp-2020-0137_ref_006_w2aab3b7c21b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Lim, MC, Chang, S-J, Yoo, HJ, Nam, B-H, Bristow, R, Park, S-Y. Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer. J Clin Oncol 2017;35:5520. https:\/\/doi.org\/10.1200\/jco.2017.35.15_suppl.5520.","DOI":"10.1200\/JCO.2017.35.15_suppl.5520"},{"key":"2025120909220889696_j_pp-2020-0137_ref_007_w2aab3b7c21b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"van Driel, WJ, Koole, SN, Sikorska, K, van Leeuwen, JHS, Schreuder, HWR, Hermans, RHM, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230\u201340. https:\/\/doi.org\/10.1056\/nejmoa1708618.","DOI":"10.1056\/NEJMoa1708618"},{"key":"2025120909220889696_j_pp-2020-0137_ref_008_w2aab3b7c21b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Elferink, F, van der Vijgh, WJ, Klein, I, ten Bokkel Huinink, WW, Dubbelman, R, McVie, JG. Pharmacokinetics of carboplatin after intraperitoneal administration. Canc Chemother Pharmacol 1988;21:57\u201360. https:\/\/doi.org\/10.1007\/bf00262740.","DOI":"10.1007\/BF00262740"},{"key":"2025120909220889696_j_pp-2020-0137_ref_009_w2aab3b7c21b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Steller, MA, Egorin, MJ, Trimble, EL, Bartlett, DL, Zuhowski, EG, Alexander, HR, et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer. Canc Chemother Pharmacol 1999;43:106\u201314. https:\/\/doi.org\/10.1007\/s002800050870.","DOI":"10.1007\/s002800050870"},{"key":"2025120909220889696_j_pp-2020-0137_ref_010_w2aab3b7c21b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Lentz, SS, Miller, BE, Kucera, GL, Levine, EA. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma. Gynecol Oncol 2007;106:207\u201310. https:\/\/doi.org\/10.1016\/j.ygyno.2007.03.022.","DOI":"10.1016\/j.ygyno.2007.03.022"},{"key":"2025120909220889696_j_pp-2020-0137_ref_011_w2aab3b7c21b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Cripe, J, Tseng, J, Eskander, R, Fader, AN, Tanner, E, Bristow, R. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent ovarian carcinoma: analysis of 30-day morbidity and mortality. Ann Surg Oncol 2015;22:655\u201361. https:\/\/doi.org\/10.1245\/s10434-014-4026-6.","DOI":"10.1245\/s10434-014-4026-6"},{"key":"2025120909220889696_j_pp-2020-0137_ref_012_w2aab3b7c21b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Argenta, PA, Sueblinvong, T, Geller, MA, Jonson, AL, Downs, LS, Carson, LF, et al. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study. Gynecol Oncol 2013;129:81\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2013.01.010.","DOI":"10.1016\/j.ygyno.2013.01.010"},{"key":"2025120909220889696_j_pp-2020-0137_ref_013_w2aab3b7c21b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Cho, HK, Lush, RM, Bartlett, DL, Alexander, HR, Wu, PC, Libutti, SK, et al. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 1999;39:394\u2013401. https:\/\/doi.org\/10.1177\/00912709922007967.","DOI":"10.1177\/00912709922007967"},{"key":"2025120909220889696_j_pp-2020-0137_ref_014_w2aab3b7c21b1b6b1ab2b2c14Aa","unstructured":"Cattel, L, De Simone, M, Passera, R, Verlengo, MC, Delprino, L. Pharmacokinetics of cisplatin in semi-closed hyperthermic peritoneal perfusion (HPP) for treatment of peritoneal carcinomatosis. Anticancer Res 2004;24:2041\u20135."},{"key":"2025120909220889696_j_pp-2020-0137_ref_015_w2aab3b7c21b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Zivanovic, O, Abramian, A, Kullmann, M, Fuhrmann, C, Coch, C, Hoeller, T, et al. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer 2015;136:699\u2013708. https:\/\/doi.org\/10.1002\/ijc.29011.","DOI":"10.1002\/ijc.29011"},{"key":"2025120909220889696_j_pp-2020-0137_ref_016_w2aab3b7c21b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Chalret du Rieu, Q, White-Koning, M, Picaud, L, Lochon, I, Marsili, S, Gladieff, L, et al. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Canc Chemother Pharmacol 2014;74:571\u201382. https:\/\/doi.org\/10.1007\/s00280-014-2525-6.","DOI":"10.1007\/s00280-014-2525-6"},{"key":"2025120909220889696_j_pp-2020-0137_ref_017_w2aab3b7c21b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Petrillo, M, Zucchetti, M, Cianci, S, Morosi, L, Ronsini, C, Colombo, A, et al. Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study. J Gynecol Oncol 2019;30:e59. https:\/\/doi.org\/10.3802\/jgo.2019.30.e59.","DOI":"10.3802\/jgo.2019.30.e59"},{"key":"2025120909220889696_j_pp-2020-0137_ref_018_w2aab3b7c21b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Rettenmaier, MA, Mendivil, AA, Abaid, LN, Brown, JV, Micha, JP, Wilcox, AM, et al. The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with carboplatin in the treatment of ovarian carcinoma. Arch Gynecol Obstet 2015;291:1381\u20136. https:\/\/doi.org\/10.1007\/s00404-014-3590-0.","DOI":"10.1007\/s00404-014-3590-0"},{"key":"2025120909220889696_j_pp-2020-0137_ref_019_w2aab3b7c21b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Mikkelsen, MS, Christiansen, T, Petersen, LK, Blaakaer, J, Iversen, LH. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer. J Surg Oncol 2019;120:550\u20137. https:\/\/doi.org\/10.1002\/jso.25603.","DOI":"10.1002\/jso.25603"},{"key":"2025120909220889696_j_pp-2020-0137_ref_020_w2aab3b7c21b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Sugarbaker, PH. Management of peritoneal-surface malignancy: the surgeon\u2019s role. Langenbeck\u2019s Arch Surg 1999;384:576\u201387. https:\/\/doi.org\/10.1007\/s004230050246.","DOI":"10.1007\/s004230050246"},{"key":"2025120909220889696_j_pp-2020-0137_ref_021_w2aab3b7c21b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Jacquet, P, Sugarbaker, PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","DOI":"10.1007\/978-1-4613-1247-5_23"},{"key":"2025120909220889696_j_pp-2020-0137_ref_022_w2aab3b7c21b1b6b1ab2b2c22Aa","unstructured":"National Cancer Institute. Common Terminology criteria for Adverse Events (CTCA) version 4.0; 2009. Available from: https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf [Accessed 31 July 2020]."},{"key":"2025120909220889696_j_pp-2020-0137_ref_023_w2aab3b7c21b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"DeGregorio, MW, Lum, BL, Holleran, WM, Wilbur, BJ, Sikic, BI. Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group. Canc Chemother Pharmacol 1986;18:235\u20138. https:\/\/doi.org\/10.1007\/bf00273393.","DOI":"10.1007\/BF00273393"},{"key":"2025120909220889696_j_pp-2020-0137_ref_024_w2aab3b7c21b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"McClay, EF, Goel, R, Andrews, P, Gorelick, S, Kirmani, S, Kim, S, et al. A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide. Br J Cancer 1993;68:783\u20138. https:\/\/doi.org\/10.1038\/bjc.1993.428.","DOI":"10.1038\/bjc.1993.428"},{"key":"2025120909220889696_j_pp-2020-0137_ref_025_w2aab3b7c21b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Jandial, DA, Brady, WE, Howell, SB, Lankes, HA, Schilder, RJ, Beumer, JH, et al. A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: an NRG Oncology\/Gynecologic Oncology Group study. Gynecol Oncol 2017;145:236\u201342. https:\/\/doi.org\/10.1016\/j.ygyno.2017.03.013.","DOI":"10.1016\/j.ygyno.2017.03.013"},{"key":"2025120909220889696_j_pp-2020-0137_ref_026_w2aab3b7c21b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Flessner, MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol 2005;288:433\u201342. https:\/\/doi.org\/10.1152\/ajprenal.00313.2004.","DOI":"10.1152\/ajprenal.00313.2004"},{"key":"2025120909220889696_j_pp-2020-0137_ref_027_w2aab3b7c21b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"de Lima Vazquez, V, Stuart, OA, Mohamed, F, Sugarbaker, PH. Extent of parietal peritonectomy does not change intraperitoneal chemotherapy pharmacokinetics. Canc Chemother Pharmacol 2003;52:108\u201312. https:\/\/doi.org\/10.1007\/s00280-003-0626-8.","DOI":"10.1007\/s00280-003-0626-8"},{"key":"2025120909220889696_j_pp-2020-0137_ref_028_w2aab3b7c21b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Rubin, J, Jones, Q, Planch, A, Bower, JD. The minimal importance of the hollow viscera to peritoneal transport during peritoneal dialysis in the rat. ASAIO transactions 1988;34:912\u20135. https:\/\/doi.org\/10.1097\/00002480-198804000-00009.","DOI":"10.1097\/00002480-198804000-00009"},{"key":"2025120909220889696_j_pp-2020-0137_ref_029_w2aab3b7c21b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Kusamura, S, Dominique, E, Baratti, D, Younan, R, Deraco, M. Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2008;98:247\u201352. https:\/\/doi.org\/10.1002\/jso.21051.","DOI":"10.1002\/jso.21051"},{"key":"2025120909220889696_j_pp-2020-0137_ref_030_w2aab3b7c21b1b6b1ab2b2c30Aa","unstructured":"BC Cancer Agency Cancer Drug Manual. Available from: http:\/\/www.bccancer.bc.ca\/drug-database-site\/Drug%20Index\/Carboplatin_monograph_1Jan2014.pdf [Accessed 31 July 2020]."}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/ahead-of-print\/article-10.1515-pp-2020-0137\/article-10.1515-pp-2020-0137.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0137\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0137\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:55:25Z","timestamp":1765277725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2020-0137\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,9,7]]},"published-print":{"date-parts":[[2020,11,25]]}},"alternative-id":["10.1515\/pp-2020-0137"],"URL":"https:\/\/doi.org\/10.1515\/pp-2020-0137","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,7]]},"article-number":"20200137"}}